Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET.

Munk Jensen M, Erichsen KD, Björkling F, Madsen J, Jensen PB, Sehested M, Højgaard L, Kjær A.

PLoS One. 2013 Dec 26;8(12):e85126. doi: 10.1371/journal.pone.0085126. eCollection 2013.

2.

Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.

Christensen MK, Erichsen KD, Olesen UH, Tjørnelund J, Fristrup P, Thougaard A, Nielsen SJ, Sehested M, Jensen PB, Loza E, Kalvinsh I, Garten A, Kiess W, Björkling F.

J Med Chem. 2013 Nov 27;56(22):9071-88. doi: 10.1021/jm4009949. Epub 2013 Nov 13.

PMID:
24164086
3.

[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.

Jensen MM, Erichsen KD, Johnbeck CB, Björkling F, Madsen J, Jensen PB, Sehested M, Højgaard L, Kjær A.

BMC Cancer. 2013 Apr 1;13:168. doi: 10.1186/1471-2407-13-168.

4.

[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.

Jensen MM, Erichsen KD, Johnbeck CB, Björkling F, Madsen J, Bzorek M, Jensen PB, Højgaard L, Sehested M, Kjær A.

PLoS One. 2013;8(1):e53410. doi: 10.1371/journal.pone.0053410. Epub 2013 Jan 4.

5.

[18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice.

Munk Jensen M, Erichsen KD, Björkling F, Madsen J, Jensen PB, Sehested M, Højgaard L, Kjær A.

PLoS One. 2012;7(11):e50618. doi: 10.1371/journal.pone.0050618. Epub 2012 Nov 30.

6.

Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells.

Michaelsen SR, Christensen CL, Sehested M, Cramer F, Poulsen TT, Patterson AV, Poulsen HS.

J Gene Med. 2012 Jul;14(7):445-58. doi: 10.1002/jgm.2630.

PMID:
22576955
7.

Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane.

Langer SW, Thougaard AV, Sehested M, Jensen PB.

Cancer Chemother Pharmacol. 2012 Feb;69(2):573-6. doi: 10.1007/s00280-011-1794-6. Epub 2011 Dec 6.

PMID:
22143379
8.

Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.

Olesen UH, Hastrup N, Sehested M.

APMIS. 2011 Apr;119(4-5):296-303. doi: 10.1111/j.1600-0463.2011.02733.x. Epub 2011 Mar 25.

PMID:
21492230
9.

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.

Olesen UH, Petersen JG, Garten A, Kiess W, Yoshino J, Imai S, Christensen MK, Fristrup P, Thougaard AV, Björkling F, Jensen PB, Nielsen SJ, Sehested M.

BMC Cancer. 2010 Dec 12;10:677. doi: 10.1186/1471-2407-10-677.

10.

Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.

Jensen MM, Erichsen KD, Björkling F, Madsen J, Jensen PB, Højgaard L, Sehested M, Kjær A.

PLoS One. 2010 Sep 24;5(9):e12965. doi: 10.1371/journal.pone.0012965.

11.

Novel small molecule drugs inhibit tumor cell metabolism and show potent anti-tumorigenic potential.

Trojel-Hansen C, Erichsen KD, Christensen MK, Jensen PB, Sehested M, Nielsen SJ.

Cancer Chemother Pharmacol. 2011 Jul;68(1):127-38. doi: 10.1007/s00280-010-1453-3. Epub 2010 Sep 18.

PMID:
20852860
12.

Synthesis and antitumor effect in vitro and in vivo of substituted 1,3-dihydroindole-2-ones.

Christensen MK, Erichsen KD, Trojel-Hansen C, Tjørnelund J, Nielsen SJ, Frydenvang K, Johansen TN, Nielsen B, Sehested M, Jensen PB, Ikaunieks M, Zaichenko A, Loza E, Kalvinsh I, Björkling F.

J Med Chem. 2010 Oct 14;53(19):7140-5. doi: 10.1021/jm100763j.

PMID:
20845961
13.

Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat.

Beck HC, Petersen J, Nielsen SJ, Morsczeck C, Jensen PB, Sehested M, Grauslund M.

Electrophoresis. 2010 Aug;31(16):2714-21. doi: 10.1002/elps.201000033. Erratum in: Electrophoresis. 2010 Oct;31(21):3619. Morszeck, Christian [corrected to Morsczeck, Christian].

PMID:
20717991
14.

A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor.

Olesen UH, Thougaard AV, Jensen PB, Sehested M.

Mol Cancer Ther. 2010 Jun;9(6):1609-17. doi: 10.1158/1535-7163.MCT-09-1130. Epub 2010 Jun 1.

15.

Ossifying thymoma associated with refractory myasthenia gravis.

Santoni-Rugiu E, Ravn J, Sehested M, Hansen K, Andersen CB.

APMIS. 2010 Apr;118(4):334-6. doi: 10.1111/j.1600-0463.2010.02595.x. No abstract available.

PMID:
20402680
16.

A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage.

Thougaard AV, Langer SW, Hainau B, Grauslund M, Juhl BR, Jensen PB, Sehested M.

Toxicology. 2010 Feb 28;269(1):67-72. doi: 10.1016/j.tox.2010.01.007. Epub 2010 Jan 15.

PMID:
20079798
17.

Anthracycline extravasation: a comprehensive review of experimental and clinical treatments.

Langer SW, Sehested M, Jensen PB.

Tumori. 2009 May-Jun;95(3):273-82. Review.

PMID:
19688963
18.

Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.

Monks A, Hose CD, Pezzoli P, Kondapaka S, Vansant G, Petersen KD, Sehested M, Monforte J, Shoemaker RH.

Anticancer Drugs. 2009 Sep;20(8):682-92. doi: 10.1097/CAD.0b013e32832e14e1.

PMID:
19606018
19.

Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.

Marquard L, Poulsen CB, Gjerdrum LM, de Nully Brown P, Christensen IJ, Jensen PB, Sehested M, Johansen P, Ralfkiaer E.

Histopathology. 2009 May;54(6):688-98. doi: 10.1111/j.1365-2559.2009.03290.x.

PMID:
19438744
20.

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.

Martin E, Thougaard AV, Grauslund M, Jensen PB, Bjorkling F, Hasinoff BB, Tjørnelund J, Sehested M, Jensen LH.

Toxicology. 2009 Jan 8;255(1-2):72-9. doi: 10.1016/j.tox.2008.10.011. Epub 2008 Oct 25.

PMID:
19010377
21.

Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.

Dejligbjerg M, Grauslund M, Litman T, Collins L, Qian X, Jeffers M, Lichenstein H, Jensen PB, Sehested M.

Mol Cancer. 2008 Sep 12;7:70. doi: 10.1186/1476-4598-7-70.

22.

Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.

Andrianov V, Gailite V, Lola D, Loza E, Semenikhina V, Kalvinsh I, Finn P, Petersen KD, Ritchie JW, Khan N, Tumber A, Collins LS, Vadlamudi SM, Björkling F, Sehested M.

Eur J Med Chem. 2009 Mar;44(3):1067-85. doi: 10.1016/j.ejmech.2008.06.020. Epub 2008 Jun 27.

PMID:
18672316
23.

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.

Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E.

Histopathology. 2008 Sep;53(3):267-77. doi: 10.1111/j.0309-0167.2008.03109.x.

24.

Photocarcinogenesis of topical tazarotene and isotretinoin alone and in combination with valproic acid in hairless mice.

Lerche CM, Philipsen PA, Sehested M, Wulf HC.

Exp Dermatol. 2008 Nov;17(11):972-4. doi: 10.1111/j.1600-0625.2008.00733.x. Epub 2008 Jul 12.

PMID:
18616577
25.

Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines.

Dejligbjerg M, Grauslund M, Christensen IJ, Tjørnelund J, Buhl Jensen P, Sehested M.

Cancer Biomark. 2008;4(2):101-9.

PMID:
18503161
26.

Monitoring the effect of belinostat in solid tumors by H4 acetylation.

Marquard L, Petersen KD, Persson M, Hoff KD, Jensen PB, Sehested M.

APMIS. 2008 May;116(5):382-92. doi: 10.1111/j.1600-0463.2008.00957.x.

27.

Anticancer agent CHS-828 inhibits cellular synthesis of NAD.

Olesen UH, Christensen MK, Björkling F, Jäättelä M, Jensen PB, Sehested M, Nielsen SJ.

Biochem Biophys Res Commun. 2008 Mar 21;367(4):799-804. doi: 10.1016/j.bbrc.2008.01.019. Epub 2008 Jan 15.

PMID:
18201551
28.

Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.

Warren KE, McCully C, Dvinge H, Tjørnelund J, Sehested M, Lichenstein HS, Balis FM.

Cancer Chemother Pharmacol. 2008 Aug;62(3):433-7. Epub 2007 Oct 25.

PMID:
17960383
29.

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.

Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M.

Biochem J. 2008 Jan 15;409(2):581-9.

PMID:
17868033
30.

Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.

Langer SW, Jensen PB, Sehested M.

Cardiovasc Toxicol. 2007;7(2):151-3. Review.

PMID:
17652821
31.

A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo.

Grauslund M, Thougaard AV, Füchtbauer A, Hofland KF, Hjorth PH, Jensen PB, Sehested M, Füchtbauer EM, Jensen LH.

Mol Pharmacol. 2007 Oct;72(4):1003-14. Epub 2007 Jul 10.

32.

DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours.

Bartkova J, Horejsí Z, Sehested M, Nesland JM, Rajpert-De Meyts E, Skakkebaek NE, Stucki M, Jackson S, Lukas J, Bartek J.

Oncogene. 2007 Nov 22;26(53):7414-22. Epub 2007 Jun 4.

PMID:
17546051
33.

Human Xip1 (C2orf13) is a novel regulator of cellular responses to DNA strand breaks.

Bekker-Jensen S, Fugger K, Danielsen JR, Gromova I, Sehested M, Celis J, Bartek J, Lukas J, Mailand N.

J Biol Chem. 2007 Jul 6;282(27):19638-43. Epub 2007 May 16.

34.

Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints.

Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L, Ørntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD, Bartek J, Gorgoulis VG.

Nature. 2006 Nov 30;444(7119):633-7.

PMID:
17136093
35.

The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.

Tumber A, Collins LS, Petersen KD, Thougaard A, Christiansen SJ, Dejligbjerg M, Jensen PB, Sehested M, Ritchie JW.

Cancer Chemother Pharmacol. 2007 Jul;60(2):275-83. Epub 2006 Nov 24.

PMID:
17124594
36.

Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis.

Tort F, Bartkova J, Sehested M, Orntoft T, Lukas J, Bartek J.

Cancer Res. 2006 Nov 1;66(21):10258-63.

37.

Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies.

Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, Jeffers M.

Mol Cancer Ther. 2006 Aug;5(8):2086-95.

38.
39.

MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases.

Illemann M, Bird N, Majeed A, Sehested M, Laerum OD, Lund LR, Danø K, Nielsen BS.

Mol Cancer Res. 2006 May;4(5):293-302.

40.

Quantitative proteomic analysis of post-translational modifications of human histones.

Beck HC, Nielsen EC, Matthiesen R, Jensen LH, Sehested M, Finn P, Grauslund M, Hansen AM, Jensen ON.

Mol Cell Proteomics. 2006 Jul;5(7):1314-25. Epub 2006 Apr 20.

41.

Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors.

Hofland KF, Thougaard AV, Dejligbjerg M, Jensen LH, Kristjansen PE, Rengtved P, Sehested M, Jensen PB.

Clin Cancer Res. 2005 Sep 15;11(18):6722-9.

42.

Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.

Jensen LH, Thougaard AV, Grauslund M, Søkilde B, Carstensen EV, Dvinge HK, Scudiero DA, Jensen PB, Shoemaker RH, Sehested M.

Cancer Res. 2005 Aug 15;65(16):7470-7.

43.

Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II.

Sorensen TK, Grauslund M, Jensen PB, Sehested M, Jensen LH.

Biochem Biophys Res Commun. 2005 Sep 2;334(3):853-60.

PMID:
16053917
44.

Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone.

Langer SW, Thougaard AV, Sehested M, Jensen PB.

Cancer Chemother Pharmacol. 2006 Jan;57(1):125-8. Epub 2005 Nov 5.

PMID:
16001176
45.

Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.

Hofland KF, Thougaard AV, Sehested M, Jensen PB.

Clin Cancer Res. 2005 May 15;11(10):3915-24.

46.

ATM activation in normal human tissues and testicular cancer.

Bartkova J, Bakkenist CJ, Rajpert-De Meyts E, Skakkebaek NE, Sehested M, Lukas J, Kastan MB, Bartek J.

Cell Cycle. 2005 Jun;4(6):838-45. Epub 2005 Jun 13.

PMID:
15846060
47.

Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage.

Syljuåsen RG, Sørensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, Helleday T, Sehested M, Lukas J, Bartek J.

Mol Cell Biol. 2005 May;25(9):3553-62.

48.

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Ørntoft T, Lukas J, Bartek J.

Nature. 2005 Apr 14;434(7035):864-70.

PMID:
15829956
49.

Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis.

Vaughn J, Huang S, Wessel I, Sorensen TK, Hsieh T, Jensen LH, Jensen PB, Sehested M, Nitiss JL.

J Biol Chem. 2005 Mar 25;280(12):11920-9. Epub 2005 Jan 12.

50.

Supplemental Content

Loading ...
Support Center